Beam Therapeutics Inc.
BEAM
Positions held
Your positionsBEAM isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Beam Therapeutics operates in the innovative biotechnology sector, focusing on gene editing technologies that have the potential to revolutionize treatment for genetic disorders.
- The company's market cap stands at approximately $2.61 billion, indicating significant investor interest and potential for growth.
- Despite recent challenges, Beam's target mean price is $52.15, suggesting a substantial upside from current levels.
- The biotechnology industry is highly competitive, with numerous companies vying for breakthroughs in gene editing, which may dilute Beam's market share.
- Beam's revenue has seen a drastic decline of 98% compared to the prior quarter, dropping from $32 million to $0.5 million.
- The operating margin has significantly compressed to -25827.1%, reflecting severe financial strain and operational inefficiencies.
Fundamentals
| Market cap | $2.54B | Enterprise value | $1.55B | Trailing P/E | — | Forward P/E | -5.19 |
| PEG | — | Price / book | 2.30 | Beta | 2.20 | Dividend yield | 0.00% |
| Revenue growth | -94.2% | Earnings growth | — | Gross margin | -1.6% | Operating margin | -258.3% |
| Profit margin | -55.4% | ROE | -8.2% | ROA | -17.0% | Debt / equity | 0.23 |
| Current ratio | 14.57 | Free cash flow | -$241.84M | Analyst recommendation | strong_buy | Mean target | $52.15 |
| 52w high | $38.26 | 52w low | $20.23 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.5M | $31.7M | $114M | $9.7M | $8.5M |
| Op margin | -25827.1% | -337.8% | -15.3% | -1307.6% | -1419.2% |
| Net income | -$123M | -$94.3M | $244M | -$113M | -$102M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$127M | -$107M | -$17.4M | -$127M | -$120M |
- Revenue -98% vs prior quarter ($0.5M vs $32M).
- Operating margin compressed to -25827.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $140M | $63.5M | $378M | $60.9M | — |
| Op margin | -274.6% | -654.3% | -46.7% | -555.6% | — |
| Net income | -$80.0M | -$377M | -$133M | -$289M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$384M | -$416M | -$176M | -$338M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Will IP Theft Allegations Against YolTech and Serapha Bio Change Beam Therapeutics' (BEAM) Narrative
2026-09-29 · Beam sues 2 biotechs, alleging theft of base editing trade secrets
2026-09-29 · Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
2026-09-28 · As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock
2026-09-28 · Cathie Wood Makes $64 Million Bet on Two Stocks
2026-09-24 · Anthropic AI Discovery Gene-Editing Stocks Falling
2026-09-24 · Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows
2026-09-23 · CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
2026-09-22 · Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
2026-09-22 · Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
2026-09-18 · Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
Price (daily)
Full chart · RSI · MACD · patterns